|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 2 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 显示文摘 | Gerard JP Conroy T Bonnetain F | 2006 | J Clin Oncol2006，24，28： | 1 |
| 3 | Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed hy maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer显示文摘 | Chauffert B Momex F Bonnetain F | 2008 | Ann On- col2008，19，9： | 1 |
| 4 | Randomized multicenter phaseⅡtrial of a biweekly regimen of fluorouracil and leucovorin(LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803显示文摘 | Bouche O Raoul JL Bonnetain F | 2004 | J Clin Oncol2004，22，21： | 1 |
| 5 | Open versus laparoscopically- assisted oesophageetomy for cancer: a multicentre randomised con- trolled phase Ill trial - the MIRO trial显示文摘 | Briez N Piessen G Bonnetain F | 2011 | BMC Cancer2011，11，： | 1 |
| 6 | Visceral fat area as a new independent predictive factor of survival in patients with meta- static renal cell carcinoma treated with antiangiogenic agents 显示文摘 | Ladoire S Bonnetain F Gauthier M | 2011 | Oncologist2011，16，1： | 1 |
| 7 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203显示文摘 | Gerard JP Conroy T Bonnetain F | 2006 | J Clin Oncol2006，24，28： | 1 |
| 8 | Combustion d'un carbonevitreux sous basses pressions d'oxygene 显示文摘 | Otterbein M Bonnetain L | 1968 | Carbon1968，6，6： | 1 |
| 9 | Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study FFCD 9803显示文摘 | Bouche O Raoul JL Bonnetain F | 2004 | J Clin Oncol2004，22，21： | 1 |
| 10 | Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study显示文摘 | Aziz Zaanan Nicolas Williet Mohamed Hebbar Tienhan Sandrine Dabakuyo Laetitia Fartoux Touraj Mansourbakht Olivier Dubreuil Olivier Rosmorduc Stéphane Cattan Franck Bonnetain Valérie Boige Julien Ta?eb | 2013 | Journal of Hepatology2013，，1： | 1 |
| 11 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203显示文摘 | Gerard JP Conroy T Bonnetain F | 2006 | J Clin Oncol2006，24，28： | 1 |
| 12 | Randomized muhicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study- FFCD 9803 显示文摘 | Bouche O Raoul JL Bonnetain F | 2004 | J Clin Oncol2004，22，21： | 1 |
| 13 | Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase Ⅲ multicentre, randomised, double blind placebo-controlled study显示文摘 | Barbare JC Bouche O Bonnetain F | 2009 | Eur J Cancer2009，45，10： | 1 |
| 14 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203显示文摘 | Gerard JP Conroy T Bonnetain F | 2006 | J Clin Oncol2006，24，28： | 1 |
| 15 | Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials 显示文摘 | Collette S Bonnetain F Paoletti X | 2008 | Annals Oncol2008，19，： | 1 |
| 16 | Locally advanced unresectable pancreatic cancer: induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: definitive results of the 2000-2001 FFCD/SFRO phase Ⅲ trial 显示文摘 | Barhoumi M Momex F Bonnetain F | 2011 | Cancer Radiother2011，15，3： | 1 |
| 17 | What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question 显示文摘 | Bonnetain F Bosset JF Gerard JP | 2012 | Eur J Cancer2012，48，12： | 1 |
| 18 | Locally advanced unresectable pancreatic cancer: induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine a- lone~ definitive results of the 2000 2001 FFCD/SFRO phase Ⅲ trial显示文摘 | Barhoumi M Mornex F Bonnetain F | 2011 | Cancer Radiother2011，15，： | 1 |
| 19 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3 -4 rectal cancers : results of FFCD 9203 显示文摘 | Gerard JP Conmy T Bonnetain F | 2006 | J Clin Oncol2006，24，28： | 1 |
| 20 | Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803显示文摘 | Bouche O Raoul JL Bonnetain F | 2004 | J Clin Oncol2004，22，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员